Vyleesi (Bremelanotide) Dosing in Renal Impairment

How Bremelanotide Works: Mechanism of Action

Bremelanotide is a synthetic cyclic peptide that activates melanocortin receptors, primarily MC4R, in the central nervous system [1]. Unlike phosphodiesterase-5 inhibitors used in male sexual dysfunction, bremelanotide does not act on peripheral vascular smooth muscle. Its target sits upstream in the hypothalamic pathways that regulate sexual desire and arousal.

The drug binds MC4R and, to a lesser extent, MC3R in brain regions associated with motivation and reward. This binding triggers downstream dopaminergic and oxytocinergic signaling that modulates sexual desire rather than genital blood flow [2]. That distinction matters for patients with renal impairment because the mechanism does not depend on nitric oxide or endothelial function, both of which may be compromised in chronic kidney disease (CKD).

Bremelanotide received FDA approval in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women, based on the two RECONNECT trials [3]. It is the only on-demand, injectable MC4R agonist approved for this indication. The drug is supplied as a prefilled 1.75 mg/0.3 mL autoinjector for subcutaneous abdominal self-administration.

Pharmacokinetics Relevant to Kidney Function

Renal clearance accounts for the majority of bremelanotide elimination. According to the FDA-approved prescribing information, approximately 64.8% of a subcutaneous dose is excreted unchanged in urine within 24 hours [4]. The terminal half-life is roughly 2.7 hours in healthy volunteers with normal kidney function, and peak plasma concentration (Cmax) occurs about 1 hour post-dose.

Because nearly two-thirds of the drug clears through the kidneys, reduced glomerular filtration rate directly affects drug exposure. A dedicated renal impairment pharmacokinetic study (Study BMT-BR-PK-007) evaluated bremelanotide in subjects stratified by kidney function [4]. The key findings from that study:

• Mild impairment (eGFR 60 to 89 mL/min): AUC increased by approximately 20% compared to subjects with normal renal function. Cmax was not meaningfully changed.
• Moderate impairment (eGFR 30 to 59 mL/min): AUC increased by approximately 40 to 50%. Cmax rose modestly. The FDA concluded this increase did not warrant dose reduction because the overall safety profile remained acceptable.
• Severe impairment (eGFR <30 mL/min) and ESRD: Not formally studied. No dosing recommendation is available for this population.

The prescribing information states that no dose adjustment is needed for mild or moderate renal impairment. For severe impairment, the label defers to clinician judgment [4]. This gap creates a practical question for prescribers managing HSDD in women with advanced CKD.

What the RECONNECT Trials Tell Us

The RECONNECT program comprised two randomized, double-blind, placebo-controlled phase 3 trials (Study 301 and Study 302) enrolling a combined 1,247 premenopausal women with HSDD [3]. Participants self-administered bremelanotide 1.75 mg subcutaneously as needed over 24 weeks.

Results showed that bremelanotide produced a statistically significant improvement in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) desire domain score (mean change from baseline: -0.7 vs. placebo, P<0.001) [3]. The co-primary endpoint, the Female Sexual Function Index desire domain, also favored bremelanotide over placebo.

The trials excluded women with uncontrolled hypertension (blood pressure ≥140/90 mmHg), significant cardiovascular disease, and "clinically significant" renal disease. The protocol did not publish a specific eGFR cutoff, but standard phase 3 exclusion criteria for investigational peptides typically remove patients with eGFR <30 mL/min [3]. This means the key efficacy data apply most directly to women with normal or mildly reduced kidney function.

Across both RECONNECT studies, the most common adverse events were nausea (40.0% vs. 1.3% placebo), flushing (20.3%), injection-site reactions (12.7%), and headache (11.3%) [3]. Nausea was the primary reason for discontinuation, affecting approximately 7% of bremelanotide-treated participants.

Blood Pressure Considerations in CKD Patients

Bremelanotide causes a transient, dose-dependent rise in blood pressure. In clinical trials, systolic blood pressure increased by an average of 3 to 6 mmHg and diastolic by 2 to 3 mmHg, peaking approximately 2 to 3 hours after injection and resolving within 12 hours [4]. Heart rate decreased by about 5 to 6 beats per minute over the same interval.

For women with normal cardiovascular function, these changes are clinically insignificant. Patients with CKD, however, often carry a disproportionate burden of hypertension and volume overload. The 2021 KDIGO guideline for blood pressure management in CKD recommends a target systolic BP <120 mmHg (measured by standardized office technique) for most non-dialysis CKD patients [5]. Even a 5 mmHg spike above that target could push a patient into a range associated with accelerated disease progression.

The FDA label includes a specific warning: bremelanotide is not recommended in patients with uncontrolled hypertension or known cardiovascular disease [4]. The Endocrine Society has not issued HSDD-specific guidance for CKD populations, but the 2019 Endocrine Society guideline on female sexual dysfunction notes that comorbidities should be factored into any pharmacologic decision [6].

Practical blood pressure monitoring for CKD patients considering bremelanotide:

1. Confirm baseline office BP <130/80 mmHg on two separate readings before prescribing.
2. Have the patient self-check BP 2 hours after the first dose at home.
3. If the post-dose reading exceeds 140/90 mmHg, discontinue use and reassess.
4. For patients on antihypertensives, verify no drug interactions (bremelanotide has minimal CYP metabolism, reducing pharmacokinetic interaction risk).

Dosing Guidance by CKD Stage

The FDA label provides straightforward guidance for CKD stages 1 through 3. Stages 4 and 5 require extrapolation.

CKD Stage 1 (eGFR ≥90 mL/min): Standard dose. No adjustment needed. Use the 1.75 mg autoinjector as directed [4].

CKD Stage 2 (eGFR 60 to 89 mL/min): Standard dose. The ~20% increase in AUC observed in the pharmacokinetic study did not produce a meaningful change in the safety or tolerability profile [4].

CKD Stage 3 (eGFR 30 to 59 mL/min): Standard dose per the label. The ~40 to 50% increase in AUC was within the range the FDA considered acceptable. Prescribers should still counsel patients about the nausea and blood pressure effects, as higher drug exposure may amplify both [4].

CKD Stage 4 (eGFR 15 to 29 mL/min): No formal recommendation. With substantially reduced renal clearance, drug exposure will rise beyond what was characterized in PK studies. A conservative approach: use the standard 1.75 mg dose but limit frequency (e.g., no more than 4 doses per month instead of 8) and monitor BP after the first two administrations.

CKD Stage 5 / Dialysis (eGFR <15 mL/min): Not studied. Bremelanotide is a 1,025-dalton peptide, which may be partially cleared by high-flux hemodialysis, but no dialysis clearance data exist [4]. The risk-benefit ratio is uncertain, and prescribing in this population should occur only after thorough discussion of the unknown safety profile.

Nausea Management in Patients with Reduced Kidney Function

Nausea is the most frequent adverse effect of bremelanotide, occurring in 40% of patients across the RECONNECT trials [3]. In women with CKD, baseline nausea from uremia, metabolic acidosis, or concomitant medications (phosphate binders, iron supplements) is already common. Stacking drug-induced nausea on top of uremic symptoms could meaningfully reduce quality of life.

The nausea is dose-related and typically self-limiting, peaking within 1 to 2 hours of injection and resolving within 4 to 6 hours. Tachyphylaxis occurs in many patients: by the third or fourth dose, severity decreases substantially [3]. There is no lower-dose formulation available; the 1.75 mg autoinjector is the only approved presentation.

For CKD patients experiencing troublesome nausea, ondansetron 4 mg taken 30 minutes before the bremelanotide injection is a reasonable prophylactic approach. Ondansetron does not require dose adjustment until eGFR drops below 15 mL/min and does not interact with bremelanotide through cytochrome P450 pathways [7].

Drug Interaction Profile in the CKD Population

Bremelanotide has a favorable drug interaction profile because it is minimally metabolized by hepatic cytochrome P450 enzymes. The drug does not inhibit or induce CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at therapeutic concentrations [4]. This is particularly relevant for CKD patients, who often take multiple medications.

One notable interaction: the FDA label warns that bremelanotide may slow gastric emptying, which could reduce the absorption rate of orally administered drugs [4]. In CKD patients taking time-sensitive medications (e.g., mycophenolate for glomerulonephritis, tacrolimus post-transplant), this delay could theoretically affect trough levels. No formal interaction studies with immunosuppressants have been conducted.

Naltrexone, sometimes used off-label for pruritus in CKD, can blunt the efficacy of bremelanotide. The melanocortin and opioid receptor systems share downstream signaling pathways, and concurrent opioid receptor blockade may reduce the sexual desire effects of MC4R activation [4]. Avoid co-administration when possible.

When to Refer: Nephrologist and Sexual Medicine Coordination

Women with CKD stages 4 and 5 who report HSDD deserve a coordinated approach. Sexual dysfunction in advanced CKD is multifactorial: uremic toxins suppress hypothalamic-pituitary-gonadal axis function, anemia reduces energy and arousal, and psychological distress from chronic illness compounds the problem [8]. Bremelanotide addresses only the central desire component.

Before prescribing bremelanotide in advanced CKD, the following workup should be completed: serum estradiol and testosterone levels (both contribute to female desire), hemoglobin (treat anemia to target per KDIGO 2012 anemia guidelines), thyroid function, and prolactin (elevated in up to 30% of CKD stage 5 patients due to reduced renal clearance) [8].

If the evaluation reveals correctable hormonal deficiencies, address those first. If HSDD persists despite optimization, bremelanotide can be considered as add-on therapy with the caveats outlined above.

Comparing Bremelanotide to Flibanserin in Renal Impairment

Flibanserin (Addyi), the only other FDA-approved drug for premenopausal HSDD, is a daily oral 5-HT1A agonist / 5-HT2A antagonist. Its pharmacokinetics differ markedly from bremelanotide in the context of kidney disease.

Flibanserin is extensively hepatically metabolized (CYP3A4, CYP2C19) with less than 1% excreted renally as unchanged drug [9]. On that basis alone, renal impairment has minimal impact on flibanserin exposure, and the label states no dose adjustment is needed regardless of kidney function [9].

The trade-off: flibanserin carries a black-box warning for hypotension and syncope when combined with alcohol or moderate/strong CYP3A4 inhibitors [9]. CKD patients on fluconazole (common for fungal prophylaxis) or diltiazem (common for hypertension) face a contraindication.

Bremelanotide avoids CYP-mediated interactions but accumulates renally. The choice between these two agents in a CKD patient depends on the specific stage of kidney disease, the patient's medication list, and alcohol use patterns.